Arbor Biotechnologies Funding: $200M Raised, Series C (2025)
Arbor Biotechnologies is a Biotech company based in Cambridge. It has raised $200M in total funding. Latest round: Series C.
Arbor Biotechnologies funding overview
Arbor Biotechnologies is a Biotech company based in Cambridge. Arbor Biotechnologies has raised $200M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in March 2025. The round record for Arbor Biotechnologies runs through 2025; nothing later has been disclosed. Investors on record include ARCH Venture Partners, TCGX, Temasek, T. Rowe Price, Vertex Pharmaceuticals. 5 distinct backers are named across the disclosed rounds.
Arbor Biotechnologies at a glance
Total raised
$200M
Latest round
Series C
Latest round date
March 2025
Industry
Biotech
Headquarters
Cambridge
Notable investors
ARCH Venture Partners, TCGX, Temasek, T. Rowe Price, Vertex Pharmaceuticals
Frequently asked about Arbor Biotechnologies funding
How much has Arbor Biotechnologies raised?
Arbor Biotechnologies has raised $200M in total disclosed funding across the rounds on record.
Who has invested in Arbor Biotechnologies?
ARCH Venture Partners, TCGX, Temasek, T. Rowe Price, Vertex Pharmaceuticals are named among the investors backing Arbor Biotechnologies.
What was the latest Arbor Biotechnologies funding round?
The most recent disclosed round is a Series C, announced in March 2025.
Where is Arbor Biotechnologies based?
Arbor Biotechnologies is based in Cambridge.
What sector does Arbor Biotechnologies operate in?
Arbor Biotechnologies is tracked under Biotech from Cambridge, with $200M in disclosed funding.
When did Arbor Biotechnologies last raise?
The last disclosed Arbor Biotechnologies round closed in March 2025 at Series C.
Every Arbor Biotechnologies figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare Biotech companies in Cambridge at a similar stage.
